Crispr Therapeutics shares tumble after significant earnings miss
David L. Motley, a director at FNB Corp (NYSE:FNB), a $5.4 billion regional bank trading below book value, has recently sold a portion of his holdings in the company. According to InvestingPro analysis, FNB currently appears undervalued based on its Fair Value estimate. According to a Form 4 filing with the Securities and Exchange Commission, Motley sold 15,000 shares of common stock on February 19, 2025, at an average price of $15.5057 per share. This transaction amounted to a total of $232,585. Notably, FNB has maintained dividend payments for 51 consecutive years, with a current yield of 3.1%.
Following the sale, Motley retains ownership of 65,343.516 shares in the company. The reported total includes shares acquired through FNB Corp’s dividend reinvestment plan and dividend equivalent units accrued on restricted stock units. For deeper insights into insider transactions and comprehensive financial analysis, including 5 additional ProTips, check out FNB’s detailed Pro Research Report on InvestingPro.
In other recent news, F.N.B. Corporation reported fourth-quarter earnings that exceeded expectations, with adjusted earnings per share reaching $0.38 compared to the consensus forecast of $0.33. However, the company’s revenue of $373.14 million fell short of Wall Street’s estimate of $408.7 million. Net interest income for the quarter was $322.2 million, slightly down from $324 million in the previous year, and the net interest margin decreased to 3.04% from 3.21% due to higher deposit costs. Total (EPA:TTEF) loans increased by 5% year-over-year to $33.9 billion, while deposits rose by 6.9% to $37.1 billion, leading to an improved loan-to-deposit ratio of 91%.
In terms of capital metrics, F.N.B. Corporation saw its common equity tier 1 (CET1) ratio rise to a record 10.6%. Despite these achievements, the company faced challenges with higher operating expenses, excluding a $10.4 million tax credit valuation allowance, primarily due to increased personnel costs. Analyst firm Raymond (NSE:RYMD) James maintained an Outperform rating on the stock, setting a price target of $19.00, and noted that the 2025 net interest income guidance is approximately $15 million above prior estimates.
Additionally, F.N.B. Corporation’s credit quality remained stable, with net charge-offs slightly exceeding predictions, while nonperforming assets increased to 0.48%. Fee revenues did not meet expectations, impacted by weaker securities commission and service charges, although bank-owned life insurance and treasury management service charges provided some offset. The guidance for fee revenues in 2025 is set about $10 million below the previous estimate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.